Instruction for use: Curantyl N 25

Dosage form: film-coated tablets, coated tablets

Active substance: Dipyridamolum

ATX

B01AC07 Dipyridamole

Pharmacological groups

Vasodilating agent [Antiaggregants]

Vasodilator [Adenosinergic agents]

Vasodilator [Angioprotectors and microcirculation correctors]

The nosological classification (ICD-10)

G93.4 Unspecified Encephalopathy: bilirubin encephalopathy; lacunarity status; Tremor when portal-systemic encephalopathy; The latent hepatic encephalopathy; Atherosclerotic encephalopathy; Hypertensive encephalopathy; hypoxic encephalopathy; dismetabolic encephalopathy; Encephalopathy; brain lesion; Porto-caval encephalopathy; Vascular encephalopathy; Traumatic encephalopathy; encephalopathy; encephalopathy; Encephalopathy secondary genesis; Encephalopathy discirculatory; Encephalopathy portocaval; epileptic encephalopathy; hemorrhagic shock and encephalopathy syndrome; Subacute spongiform encephalopathy

I67.9 Cerebrovascular disease, unspecified: lacunarity status; Angioneyropatiya; Arterial angiopathy; brain hypoxia; Encephalopathy; cerebral vascular disease and age-related; Coma in violation of cerebral circulation; Metabolic and cerebrovascular disorders; Violation of the blood supply to the brain; Cerebrovascular accidents; Violation of brain functions; Violation of the functions of the cerebral cortex; Violation of cerebral circulation; Cerebrovascular insufficiency; Acute cerebrovascular insufficiency; Acute ischemic attack; The defeat of the brain vessels; The progression of destructive changes in the brain; Disorders of cerebral circulation; The syndrome of cerebral insufficiency; Cerebral vascular insufficiency; Vascular encephalopathy; Vascular diseases of the brain; Vascular brain disorders; Vascular lesions of the brain; Functional brain disorders; Chronic cerebral ischemia; Chronic heart failure; Chronic cerebrovascular insufficiency; Chronic cerebrovascular insufficiency; Chronic violation of the blood supply to the brain; Cerebral insufficiency; Cerebral organic failure; encephalasthenia; cerebroasthenic syndrome; Cerebrovascular disease; Cerebrovascular pathology; cerebrovascular disease; cerebrovascular disorders; cerebrovascular disorders; Encephalopathy discirculatory

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I82 Embolism and thrombosis of other veins: Recurrent venous thrombosis; Postoperative thrombosis; Venous thrombosis; Acute venous thromboembolism; Recurrent vein thrombosis; Venous thrombosis; Thrombosis of veins of internal organs; Venous thrombosis; Deep vein thrombosis; Thrombosis of blood vessels; Vascular thrombosis; Thrombosis of veins; Deep vein thrombosis; Thromboembolic diseases; Thromboembolism of veins; Severe venous thrombosis; Embolism; Embolism of veins; Thromboembolic complications

P02.2 Fetus and newborn affected by unspecified and other morphological and functional abnormalities of the placenta

Structure and Composition

Curantil 25

1 pill

Dipyridamole - 25 mg

Auxiliary substances: lactose monohydrate; corn starch; gelatin; Magnesium stearate; talc; Sucrose; Calcium carbonate; Magnesium carbonate light basic; Macrogol 6000; Glucose syrup; Titanium dioxide; Polyvidone K25; Carnauba wax; Dye quinoline yellow (dye E104)

In glass bottles of 100 pcs .; In the box 1 bottle.

Kurantil N 25

Film-coated tablets.

Dipyridamole - 25 mg

Auxiliary substances: lactose monohydrate; corn starch; gelatin; Starch of carboxymethyl sodium salt (type A); Silicon dioxide highly dispersed; Magnesium stearate

Composition of the membrane: hypromellose; talc; Macrogol 6000; Titanium dioxide; Dye quinoline yellow (dye E104); Simethicone emulsion

In bottles of glass for 120 pcs .; In the box 1 bottle.

Curantil N 75

Coated tablets.

Dipyridamole - 75 mg

Auxiliary substances: lactose monohydrate; corn starch; gelatin; Starch of carboxymethyl sodium salt (type A); Silicon dioxide highly dispersed; Magnesium stearate

Composition of the membrane: hypromellose; talc; Macrogol 6000; Titanium dioxide; Dye quinoline yellow (dye E104); Simethicone emulsion

In a blistere of 20 pcs .; In the box 2 blisters.

Description

Pill: from yellow to greenish-yellow, with smooth surfaces, have a uniform appearance.

The tablets covered with a cover: ploskotsilindricheskie, yellow color.

Characteristic

The pyrimidine derivative.

Pharmachologic effect

Mode of action - Immunomodulatory, antiaggregational, angioprotective.

Competitively inhibits adenosine deaminase, promoting the accumulation of adenosine, involved in the regulation of coronary blood flow, and the ability of platelets to aggregate and adhesion. It blocks phosphodiesterase and increases the content in cAMP cells. As a derivative of pyrimidine, Couantil is an inducer of interferon and has a modulating effect on the functional activity of the interferon system; Increases non-specific antiviral resistance to viral infections.

Pharmacodynamics

Reduces the resistance of coronary arteries at the level of small branches and arterioles, increases the number of collaterals and collateral blood flow; Increases the concentration of adenosine and the synthesis of ATP in the myocardium, improves its contractility, reduces TPR, lowers blood pressure, inhibits platelet aggregation (improves microcirculation, prevents arterial thrombosis), normalizes venous outflow; Reduces the resistance of cerebral vessels, corrects placental blood flow; With the threat of preeclampsia prevents dystrophic changes in the placenta, eliminates hypoxia of the fetal tissues, promotes the accumulation of glycogen in them; Has a modulating effect on the functional activity of the interferon system, increases the nonspecific antiviral resistance to viral infections.

Pharmacokinetics

Quickly absorbed from the stomach (most) and the small intestine (a small amount). Almost completely binds to plasma proteins. Cmax - within 1 h after administration. Accumulates, first of all, in the heart and red blood cells. Metabolized by the liver by binding to glucuronic acid, is excreted with bile in the form of monoglucuronide. For tablets T1 / 2 is 10 h ± 2.2 h.

Indications of the drug Curantyl 25

Treatment and prevention of cerebral circulation, discirculatory encephalopathy, prophylaxis of arterial and venous thromboses and their complications, thromboembolism after cardiac valve prosthesis operation, placental insufficiency in complicated pregnancy, as part of complex therapy for any microcirculation disorders, as an inducer of interferon and immunomodulator for prevention and Treatment of influenza, ARVI.

Contraindications

Hypersensitivity, acute myocardial infarction, unstable angina, stenosing coronary artery atherosclerosis, decompensated heart failure, subaortic stenosis of the aorta, hypotension and hypertension (severe forms), collapse, arrhythmia, gastric and duodenal ulcer (at the acute stage), hepatic and / or Renal failure, hemorrhagic diathesis, age up to 12 years.

Pregnancy and breast-feeding

Perhaps under the supervision of a doctor and according to the testimony.

Side effects

Extremely rarely possible nausea, vomiting, diarrhea, dizziness, headache, myalgia; Hypotension, transient hyperemia of the face, tachycardia; Skin allergic reactions.

Interaction

Weaken the effect of xanthine derivatives (for example, coffee, tea); Strengthen - oral indirect anticoagulants (heparin, thrombolytics) or acetylsalicylic acid (the risk of hemorrhagic complications increases). Increases the antihypertensive effect of antihypertensive agents, weakens the cholinergic properties of cholinesterase inhibitors. The anti-aggregation effect increases with antibiotic-cephalosporins (cefamandol, cefoperazone, cefotetan). Antacids reduce the maximum concentration due to decreased absorption.

Dosing and Administration

Inside, on an empty stomach, not chewing, drinking a small amount of liquid.

To reduce platelet aggregation: 75-225 mg / day in several doses, in severe cases, the dose is increased to 600 mg / day.

For the prevention of influenza and other acute respiratory viral infections, especially during epidemics: 50 mg / day (2 tablets or 2 drops of 25 mg once) once a week for 4-5 weeks.

For the prevention of recurrences, in patients with respiratory viral infections often infected: 100 mg / day according to the scheme: 50 mg (2 tablets or 2 tablets 25 mg each) 2 times a day at intervals of 2 hours, 1 time per week in The course of 8-10 weeks.

Precautionary measures

You should avoid the use of natural coffee and tea (possibly weakening the effect).

Manufacturer

"Berlin-Chemie AG / Menaryini Group", Germany.

Storage conditions of the drug Curantyl 25

In the dark place at a temperature of no higher than 30° C.

Keep out of the reach of children.

The shelf life of the drug Curantyl 25

Coated tablets 25 mg - 3 years.

Coated tablets 75 mg - 3 years.

Pills 25 mg - 5 years.

Do not use beyond the expiration date printed on the package.